Concord Biotech Limited has made the audio recording of its earnings call available to investors and stakeholders. The conference call was conducted on August 3, 2026, at 3:30 P.M. (IST), following the release of the company’s unaudited financial results for the first quarter ended June 30, 2026. This disclosure ensures transparency and provides market participants with direct access to management’s commentary on the quarterly performance.

The filing was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It serves as a follow-up to an earlier intimation dated July 28, 2026, which had notified the stock exchanges regarding the scheduled earnings call. The submission covers both standalone and consolidated financial results for the period.

Key Details

The audio recording is hosted on the company’s official website. Investors can access the file directly through the provided link to review management’s insights into the financial outcomes and operational updates for the quarter.

Regulatory Compliance

The notification was addressed to the Listing Departments of both the National Stock Exchange of India Limited and BSE Limited. Paritosh Trivedi, Company Secretary and Compliance Officer of Concord Biotech Limited, signed the communication. The filing confirms that the proceedings were completed successfully and invites stakeholders to take the information on record.

Concord Biotech Limited shareholders approved all six resolutions at its 41st Annual General Meeting (AGM) held on July 31, 2026, including a contentious special resolution to enhance lending limits to group companies. The approval enables the biotechnology firm to advance loans and provide guarantees to subsidiaries, associates, and joint ventures pursuant to Section 185 of the Companies Act, 2013. However, the resolution faced significant resistance from institutional investors, highlighting a divergence in governance sentiment between promoter-aligned and independent public stakeholders.

The meeting was conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), with Central Depository Services (India) Limited (CDSL) facilitating remote e-voting from July 28, 2026, to July 30, 2026. Ashish Shah of Ashish Shah & Associates served as the scrutinizer, submitting his consolidated report on July 31, 2026, in compliance with Section 108 of the Companies Act, 2013 and Rule 20(xi) of the Companies (Management and Administration) Rules, 2014. Paritosh Trivedi, Company Secretary and Compliance Officer, submitted the voting results to the National Stock Exchange of India Limited and BSE Limited on August 1, 2026, under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results Overview

A total of 83,770 shareholders were on record as of July 24, 2026. No shareholders attended in person or via proxy; participation was exclusively through VC/OAVM (38 shareholders: four promoters, 34 public) and remote e-voting. All resolutions passed, but the margin varied significantly based on investor category.

Divergent Sentiment on Loan Limits

The special resolution for enhanced loan limits revealed a stark split in shareholder opinion. Promoter and promoter group shareholders, holding 46,116,608 shares, abstained from voting due to their interest in the agenda. Consequently, the outcome depended entirely on public shareholders. Public non-institutional shareholders voted overwhelmingly in favor with 99.99% support. In contrast, public institutional shareholders opposed the measure, with 56.60% voting against and only 43.40% in favor. Despite this institutional resistance, the resolution passed with 35,391,774 votes in favor out of 43,353,536 valid votes polled.

Other resolutions enjoyed near-unanimous support. The adoption of standalone and consolidated financial statements for FY26 received 99.69% affirmative votes. The dividend declaration was approved with 99.98% support. The re-appointment of Mr. Ankur Vaid (DIN: 01857225), who retires by rotation, secured 99.70% support. Similarly, the appointment of Mrs. Ekta Gupta as an independent director passed with negligible opposition, reflecting broad consensus on board composition.

What the Numbers Show

The voting pattern underscores a growing disconnect between institutional investors and retail shareholders regarding corporate governance practices at Concord Biotech. While institutions expressed clear disapproval of the enhanced lending limits—likely citing risk management concerns—the overwhelming support from non-institutional public shareholders ensured the resolution's passage. This dynamic suggests that while institutional scrutiny is intensifying, promoter-aligned or retail investor sentiment continues to drive key strategic approvals, potentially insulating management decisions from broader market skepticism.